High pathologic complete remission rate with liposome-encapsulated doxorubicin plus paclitaxel plus trastuzumab as primary treatment in HER-2 positive operable breast cancer: clinical experience

被引：0
|
作者：
Gavila, J. [1 ]
Guerrero-Zotano, A. [1 ]
Climent, M. A. [1 ]
Blanch, S. [1 ]
Guillem, V. [1 ]
Camp, J. [1 ]
Tortajada, M. I. [1 ]
Gozalbo, F. [1 ]
Vidal, P. [1 ]
Ruiz, A. [1 ]
机构：
[1] Fdn Inst Valenciano Oncol, Valencia, Spain
来源：
EJC SUPPLEMENTS | 2010年 / 8卷 / 03期
关键词：
D O I：
10.1016/S1359-6349(10)70066-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：68 / 69
页数：2
相关论文
共 50 条
  • [1] Liposome-encapsulated doxorubicin plus paclitaxel and trastuzumab as neoadjuvant chemotherapy for operable and locally advanced breast cancer.
    Rossi, D.
    Pistilli, B.
    Morale, D.
    Baldelli, A.
    Casadei, V.
    Benedetti, G.
    Fedeli, S. Luzi
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [2] Neoadjuvant chemotherapy with nonpegylated liposome-encapsulated doxorubicin (NPLD) plus cyclophosphamide followed by trastuzumab plus nabpaclitaxel for HER2-positive breast cancer (BC).
    Saracchini, Silvana
    Foltran, Luisa
    Bassini, Anna
    Faro, Sandro Su
    Lorenzon, Michele
    Micheli, Elvia
    Favero, Alessandro
    Marus, Wally
    Del Conte, Alessandro
    Gusso, Giuseppina
    Manente, Stefania
    Tumolo, Salvatore
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [3] Trastuzumab plus paclitaxel in HER-2 positive metastatic breast cancer: A single institutional experience
    Capobianco, A. M. L.
    Di Leo, P.
    Bochicchio, A. M.
    Coccaro, M.
    Romano, G.
    Tartarone, A.
    Ardito, R.
    Musto, C.
    Barone, M.
    Guarigli, R.
    Di Renzo, N.
    ANNALS OF ONCOLOGY, 2005, 16 : 141 - 142
  • [4] Lapatinib plus trastuzumab for HER-2 positive metastatic breast cancer: experience of use
    Garcia Munoz, C.
    Cortijo Cascajares, S.
    Canamares Orbis, I.
    Goyache Goni, M. D. P.
    Ferrari Piquero, J. M.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2013, 35 (05) : 892 - 893
  • [5] Trastuzumab plus Paclitaxel in HER2-positive Breast Cancer
    不详
    GYNAKOLOGE, 2016, 49 (08): : 558 - 558
  • [6] Phase II study of liposome-encapsulated doxorubicin plus cyclophosphamide, followed by sequential trastuzumab plus docetaxel as primary systemic therapy for breast cancer patients with HER2 overexpression or amplification
    Saracchini, S.
    Foltran, L.
    Tuccia, F.
    Bassini, A.
    Sulfaro, S.
    Micheli, E.
    Del Conte, A.
    Bertola, M.
    Gion, M.
    Lorenzon, M.
    Tumolo, S.
    BREAST, 2013, 22 (06): : 1101 - 1107
  • [7] High pathologic complete response after primary chemotherapy in patients treated with weekly paclitaxel followed by FEC chemotherapy with simultaneous trastuzumab in Her-2 positive operable breast cancer
    Pernas, S.
    Gil Gil, M.
    Urruticoechea, A.
    Fernandez-Ortega, A.
    Falo, C.
    Piulats, J. M.
    Prieto, L.
    Pla, M. J.
    Moreno, A.
    Germa, J. R.
    ANNALS OF ONCOLOGY, 2006, 17 : 96 - 96
  • [8] Complete response after docetaxel plus pertuzumab plus trastuzumab chemotherapy for multimetastatic positive Her-2 breast cancer
    Lai-Tiong, F.
    Van-Hulst, S.
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2018, 39 (04) : 662 - 664
  • [9] Liposome-encapsulated doxorubicin plus cyclophosphamide followed by trastuzumab plus docetaxel as neoadjuvant therapy for HER2-positive breast cancer (BC): A multicenter single-arm phase II study
    Saracchini, Silvana
    Foltran, Luisa
    Sulfaro, Sandro
    Tuccia, Fausto
    Del Conte, Alessandro
    Bertolla, Manuella
    Bassini, Anna
    Micheli, Elvia
    Manente, Stefania
    Gusso, Giuseppina
    Baresic, Tania
    Tumoio, Salvatore
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [10] Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
    Romond, EH
    Perez, EA
    Bryant, J
    Suman, VJ
    Geyer, CE
    Davidson, NE
    Tan-Chiu, E
    Martino, S
    Paik, S
    Kaufman, PA
    Swain, SM
    Pisansky, TM
    Fehrenbacher, L
    Kutteh, LA
    Vogel, VG
    Visscher, DW
    Yothers, G
    Jenkins, RB
    Brown, AM
    Dakhil, SR
    Mamounas, EP
    Lingle, WL
    Klein, PM
    Ingle, JN
    Wolmark, N
    NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (16): : 1673 - 1684
12345